PHARMACY

Clinic operator Christie Clinic sells two pharmacies to Walgreens

BY Michael Johnsen

CHAMPAIGN, Ill. — Christie Clinic last week announced it had entered into a purchase agreement with Walgreens for the sale of two of the former’s pharmacy operations.

Walgreens will lease the space currently occupied by Christie Clinic for its new operations. The transfer is expected to be completed by the end of March. Walgreens plans to keep both pharmacy locations open and is renovating the facilities, including new signage.

Both pharmacies will be closed on March 31 and April 1 for minor renovations, as well as operational changes, and will open as Walgreens at 8:00 a.m. on April 2, the clinic operator said.

Christie Clinic operates 14 clinic locations throughout east central Illinois, as well as the Christie Clinic Cancer Center and C U Sleep, which houses the Department of Sleep Medicine.

 


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

FDA accepts NDA filing for Impax’s Parkinson’s disease treatment

BY Allison Cerra

HAYWARD, Calif. — The Food and Drug Administration has accepted a new drug application for the treatment of idiopathic Parkinson’s disease.

Impax Pharmaceuticals, the branded products division of Impax Labs, said it filed its NDA for the investigational drug IPX066, an extended-release capsule formulation of carbidopa-levodopa, for review in December 2011. IPX066 has been licensed to GlaxoSmithKline for countries outside the United States and Taiwan for development and marketing.

The Prescription Drug User Fee Date for a decision by the FDA is Oct. 21, Impax said.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

FDA approves Korlym for Cushing’s syndrome

BY Alaric DeArment

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug for a rare disorder that previously had no approved medical therapies, the agency said.

The FDA announced the approval of Menlo Park, Calif.-based Corcept Therapeutics’ Korlym (mifepristone) for endogenous Cushing’s syndrome, a disorder that results from overproduction of cortisol, a steroid hormone that increases blood-sugar levels.

The drug is approve for patients with the disease who have Type 2 diabetes or glucose intolerance and are not candidates for surgery or who have not responded to surgery, and the agency said about 5,000 patients will be eligible for treatment.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?